CoChat

Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex

Open access

The DOI matches its Crossref record; 123 of the 123 references it cites were found in a registry or an index.

Abstract

Genetic studies have shown that the tuberous sclerosis complex (TSC) 1–TSC2–mammalian target of Rapamycin (mTOR) and the Hippo–Yes-associated protein 1 (YAP) pathways are master regulators of organ size, which are often involved in tumorigenesis. The crosstalk between these signal transduction pathways in coordinating environmental cues, such as nutritional status and mechanical constraints, is crucial for tissue growth. Whether and how mTOR regulates YAP remains elusive. Here we describe a novel mouse model of TSC which develops renal mesenchymal lesions recapitulating human perivascular epithelioid cell tumors (PEComas) from patients with TSC. We identify that YAP is up-regulated by mTOR in mouse and human PEComas. YAP inhibition blunts abnormal proliferation and induces apoptosis of TSC1–TSC2-deficient cells, both in culture and in mosaic Tsc1 mutant mice. We further delineate that YAP accumulation in TSC1/TSC2-deficient cells is due to impaired degradation of the protein by the autophagosome/lysosome system. Thus, the regulation of YAP by mTOR and autophagy is a novel mechanism of growth control, matching YAP activity with nutrient availability under growth-permissive conditions. YAP may serve as a potential therapeutic target for TSC and other diseases with dysregulated mTOR activity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20140341

Cites

123 of 123 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Mosaic-Tsc1KO mice develop multisystem lesions showing similarities with human TSC. (a) Genomic DNA was prepared from control (ctrl) and mosaic-Tsc1KO mice 1.5 mo after tamoxifen injection, and the floxed/mutant alleles were detected by PCR in the indicated organs. (b) Expression of phospho-rpS6 in cerebral cortex sections from ctrl and mosaic-Tsc1KO mice was analyzed by immunohistochemical staining. (c) Skin samples of ctrl and mosaic-Tsc1KO mice were stained for ICAM-1 expression and using Trichrome. Arrows indicate ICAM-1+ vessels. (d) Plasma urea concentrations were determined in ctrl and mosaic-Tsc1KO kidneys (Mean ± SEM; n = 4 mice/group; *, P < 0.05). Bars, 100 µm. Three independent pregnant females were injected with tamoxifen. For immunohistochemistry analysis, similar stainings were found in four different ctrl/mosaic-Tsc1KO mice (6 wk of age, two sections per mouse).
Figure 1. Mosaic-Tsc1KO mice develop multisystem lesions showing similarities with human TSC. (a) Genomic DNA was prepared from control (ctrl) and mosaic-Tsc1KO mice 1.5 mo after tamoxifen injection, and the floxed/mutant alleles were detected by PCR in the indicated organs. (b) Expression of phospho-rpS6 in cerebral cortex sections from ctrl and mosaic-Tsc1KO mice was analyzed by immunohistochemical staining. (c) Skin samples of ctrl and mosaic-Tsc1KO mice were stained for ICAM-1 expression and using Trichrome. Arrows indicate ICAM-1+ vessels. (d) Plasma urea concentrations were determined in ctrl and mosaic-Tsc1KO kidneys (Mean ± SEM; n = 4 mice/group; *, P < 0.05). Bars, 100 µm. Three independent pregnant females were injected with tamoxifen. For immunohistochemistry analysis, similar stainings were found in four different ctrl/mosaic-Tsc1KO mice (6 wk of age, two sections per mouse).CC BY-NC-SA · PubMed Central
Figure 2. Mosaic-Tsc1KO mice develop renal mesenchymal lesions recapitulating PEComas associated with human TSC. Kidneys from ctrl (n = 3) and mosaic-Tsc1KO (n = 3) mice were analyzed at 6 wk of age. (a) Macroscopic photos and representative H&E staining. Arrows indicate hemorrhages. (b–d) Expression of vimentin (b and c), phospho-rpS6, and Ki67 (c) and Hmb45/Pmel (d) was assessed by immunohistochemistry. H&E staining was shown on left in c. Arrows in b indicate vimentin+ microhamartomas in mosaic-Tsc1KO kidneys. For immunohistochemistry analysis, similar stainings were found in three different ctrl/mosaic-Tsc1KO mice (three sections per mouse). (e) Expression of Mart1, Cathepsin K, Pmel, and Tyrp1 mRNA was assessed by qRT-PCR. Mean ± SEM; n = 3 mice/group; *, P < 0.05. (f) Expression of α-SMA, Mart1, p-rpS6, and total rpS6 protein was assessed by Immunoblot. (g) Expression of the indicated proteins in three distinct human angiomyolipoma (AML) samples was assessed by immunohistochemistry. Arrows indicate the microhamartoma. Bar, 100 µm unless otherwise indicated. Insets show higher magnification of the lesions indicated with squares.
Figure 2. Mosaic-Tsc1KO mice develop renal mesenchymal lesions recapitulating PEComas associated with human TSC. Kidneys from ctrl (n = 3) and mosaic-Tsc1KO (n = 3) mice were analyzed at 6 wk of age. (a) Macroscopic photos and representative H&E staining. Arrows indicate hemorrhages. (b–d) Expression of vimentin (b and c), phospho-rpS6, and Ki67 (c) and Hmb45/Pmel (d) was assessed by immunohistochemistry. H&E staining was shown on left in c. Arrows in b indicate vimentin+ microhamartomas in mosaic-Tsc1KO kidneys. For immunohistochemistry analysis, similar stainings were found in three different ctrl/mosaic-Tsc1KO mice (three sections per mouse). (e) Expression of Mart1, Cathepsin K, Pmel, and Tyrp1 mRNA was assessed by qRT-PCR. Mean ± SEM; n = 3 mice/group; *, P < 0.05. (f) Expression of α-SMA, Mart1, p-rpS6, and total rpS6 protein was assessed by Immunoblot. (g) Expression of the indicated proteins in three distinct human angiomyolipoma (AML) samples was assessed by immunohistochemistry. Arrows indicate the microhamartoma. Bar, 100 µm unless otherwise indicated. Insets show higher magnification of the lesions indicated with squares.CC BY-NC-SA · PubMed Central
Figure 3. Mosaic-Tsc1KO mice develop renal H-caldesmon+ mesenchymal lesions containing CD31+ endothelial cells and PDGFRβ+/αSMA+ pericytes. (a and b) Kidney tissues were isolated from ctrl and mosaic-Tsc1KO mice at 6 wk of age and analyzed by immunofluorescence for H-caldesmon and CD31 (a) or PDGFRβ and αSMA (b). Arrows in b indicate PDGFRβ– and αSMA–double-positive pericytes. (c) Expression of β-gal and vimentin on kidney sections from Ctrl;R26-floxstop-LacZ and mosaic-Tsc1KO;R26-floxstop-LacZ mice was assessed by immunofluorescence. Arrows indicate β-gal+ cells and arrowheads show β-gal negative cells. Insets show higher magnification of tissue indicated with squares. Similar stainings were found in three different mice/genotype (three sections per each mouse). Bars: (A–C) 100 µm.
Figure 3. Mosaic-Tsc1KO mice develop renal H-caldesmon+ mesenchymal lesions containing CD31+ endothelial cells and PDGFRβ+/αSMA+ pericytes. (a and b) Kidney tissues were isolated from ctrl and mosaic-Tsc1KO mice at 6 wk of age and analyzed by immunofluorescence for H-caldesmon and CD31 (a) or PDGFRβ and αSMA (b). Arrows in b indicate PDGFRβ– and αSMA–double-positive pericytes. (c) Expression of β-gal and vimentin on kidney sections from Ctrl;R26-floxstop-LacZ and mosaic-Tsc1KO;R26-floxstop-LacZ mice was assessed by immunofluorescence. Arrows indicate β-gal+ cells and arrowheads show β-gal negative cells. Insets show higher magnification of tissue indicated with squares. Similar stainings were found in three different mice/genotype (three sections per each mouse). Bars: (A–C) 100 µm.CC BY-NC-SA · PubMed Central
Figure 4. YAP is up-regulated by mTOR in renal lesions of mosaic-Tsc1KO mice and human angiomyolipoma. (a and b) Expression of indicated genes was determined by qRT-PCR (a) and immunoblot analysis (b) in kidney samples from Ctrl mice treated with placebo, mosaic-Tsc1KO mice treated with placebo, or temsirolimus. Mice were injected i.p. with vehicle or temsirolimus (5 mg/kg) every other day for 2 wk before sacrifice. Mice were sacrificed at 6 wk of age. Mean ± SEM; n = 3 mice/group; *, P < 0.05, **, P < 0.01. (c) Expression of indicated proteins was analyzed by immunoblot in nuclear and cytoplasmic protein extractions from ctrl and mosaic-Tsc1KO mouse kidney samples. Similar results were found in three different mice/genotype. (d) YAP expression was assessed on kidney sections from ctrl and mosaic-Tsc1KO mice by immunohistochemistry. Arrows indicate cells with YAP nuclear localization. Bars, 100 µm. Similar stainings were found in three different mice/genotype (three sections per each mouse). (e) Expression of indicated proteins was analyzed by immunoblot in control human kidney and angiomyolipoma samples. (f and g) YAP expression was analyzed by immunohistochemistry on human angiomyolipoma samples (N, normal kidney; T, Tumor). Arrows indicate cells with YAP nuclear localization. Bars, 100 µm. Insets show higher magnification of the lesions indicated with squares. Similar results were found in 7/7 different human angiomyolipoma samples.
Figure 4. YAP is up-regulated by mTOR in renal lesions of mosaic-Tsc1KO mice and human angiomyolipoma. (a and b) Expression of indicated genes was determined by qRT-PCR (a) and immunoblot analysis (b) in kidney samples from Ctrl mice treated with placebo, mosaic-Tsc1KO mice treated with placebo, or temsirolimus. Mice were injected i.p. with vehicle or temsirolimus (5 mg/kg) every other day for 2 wk before sacrifice. Mice were sacrificed at 6 wk of age. Mean ± SEM; n = 3 mice/group; *, P < 0.05, **, P < 0.01. (c) Expression of indicated proteins was analyzed by immunoblot in nuclear and cytoplasmic protein extractions from ctrl and mosaic-Tsc1KO mouse kidney samples. Similar results were found in three different mice/genotype. (d) YAP expression was assessed on kidney sections from ctrl and mosaic-Tsc1KO mice by immunohistochemistry. Arrows indicate cells with YAP nuclear localization. Bars, 100 µm. Similar stainings were found in three different mice/genotype (three sections per each mouse). (e) Expression of indicated proteins was analyzed by immunoblot in control human kidney and angiomyolipoma samples. (f and g) YAP expression was analyzed by immunohistochemistry on human angiomyolipoma samples (N, normal kidney; T, Tumor). Arrows indicate cells with YAP nuclear localization. Bars, 100 µm. Insets show higher magnification of the lesions indicated with squares. Similar results were found in 7/7 different human angiomyolipoma samples.CC BY-NC-SA · PubMed Central
Figure 5. YAP is required for the abnormal proliferation and survival of TSC1/2-null cells in vitro. (a and b) Expression of indicated proteins was analyzed by immunoblot in Tsc2+/+ and Tsc2−/− MEFs (these MEFs were generated in p53−/− background) cultured with or without serum for 24 h. Similar results were observed in three independent experiments. (c–e) Tsc2+/+ and Tsc2−/− MEFs transfected with siCtrl or siYAP were cultured in serum starvation conditions for a 72-h period. (c) Cell number was counted in different groups. Three independent experiments were performed and analyzed (Mean ± SEM; **, P < 0.01). (d) Expression of YAP protein was analyzed by immunoblot at the 24-h time point. Similar results were observed in three independent experiments. (e) Apoptotic cells were identified by TUNEL assay at the 48-h time point. The percentage of TUNEL+ cells was determined by counting TUNEL+ nuclei among at least 500 cells in distinct fields of each experiment. Three independent experiments were performed and analyzed. Mean ± SEM; *, P < 0.05, **, P < 0.01. (f and g) Tsc2+/+ and Tsc2−/− MEFs were cultured under serum starvation conditions and treated with DMSO or Verteporfin for a 72-h period. (f) Cell number was counted. Three independent experiments were performed and analyzed. Mean ± SEM; *, P < 0.05, **, P < 0.01. (g) Expression of Ctgf mRNA was assessed by qRT-PCR in different treatments. Three independent experiments were performed and analyzed. Mean ± SEM; *, P < 0.05, **, P < 0.01, ***, P < 0.001. (h) Expression of indicated proteins was analyzed by immunoblot in HEK293 cells transfected with siRNAs against TSC1, TSC2, or siCtrl. YAP protein level was normalized with β-actin. Four independent experiments were performed and analyzed. Mean ± SEM; *, P < 0.05. (i) Percentage of BrdU+ HEK293 cells with indicated treatments under serum deprivation conditions for 24 h was assessed by 3-h BrdU pulse-labeling before harvest. Three independent experiments were performed and analyzed. Mean ± SEM; **, P < 0.01, ***, P < 0.001.
Figure 5. YAP is required for the abnormal proliferation and survival of TSC1/2-null cells in vitro. (a and b) Expression of indicated proteins was analyzed by immunoblot in Tsc2+/+ and Tsc2−/− MEFs (these MEFs were generated in p53−/− background) cultured with or without serum for 24 h. Similar results were observed in three independent experiments. (c–e) Tsc2+/+ and Tsc2−/− MEFs transfected with siCtrl or siYAP were cultured in serum starvation conditions for a 72-h period. (c) Cell number was counted in different groups. Three independent experiments were performed and analyzed (Mean ± SEM; **, P < 0.01). (d) Expression of YAP protein was analyzed by immunoblot at the 24-h time point. Similar results were observed in three independent experiments. (e) Apoptotic cells were identified by TUNEL assay at the 48-h time point. The percentage of TUNEL+ cells was determined by counting TUNEL+ nuclei among at least 500 cells in distinct fields of each experiment. Three independent experiments were performed and analyzed. Mean ± SEM; *, P < 0.05, **, P < 0.01. (f and g) Tsc2+/+ and Tsc2−/− MEFs were cultured under serum starvation conditions and treated with DMSO or Verteporfin for a 72-h period. (f) Cell number was counted. Three independent experiments were performed and analyzed. Mean ± SEM; *, P < 0.05, **, P < 0.01. (g) Expression of Ctgf mRNA was assessed by qRT-PCR in different treatments. Three independent experiments were performed and analyzed. Mean ± SEM; *, P < 0.05, **, P < 0.01, ***, P < 0.001. (h) Expression of indicated proteins was analyzed by immunoblot in HEK293 cells transfected with siRNAs against TSC1, TSC2, or siCtrl. YAP protein level was normalized with β-actin. Four independent experiments were performed and analyzed. Mean ± SEM; *, P < 0.05. (i) Percentage of BrdU+ HEK293 cells with indicated treatments under serum deprivation conditions for 24 h was assessed by 3-h BrdU pulse-labeling before harvest. Three independent experiments were performed and analyzed. Mean ± SEM; **, P < 0.01, ***, P < 0.001.CC BY-NC-SA · PubMed Central
Figure 6. Verteporfin treatment inhibits proliferation and induces apoptosis of Tsc1-null cells in vivo. Mice were administered i.p. with vehicle or verteporfin at a dose of 100 mg/kg every other day for 10 d before sacrifice. Mice were sacrificed at 6 wk of age. Three independent experiments were performed and mice in different treatments were pooled for analysis. (a) Kidney/body weight ratio of Ctrl and mosaic-Tsc1KO mice treated with placebo or Verteporfin. n = 3 mice/group. Mean ± SEM; *, P < 0.05, ***, P < 0.001. (b) Representative pictures of hematoxylin and eosin staining of kidney sections from Ctrl and mosaic-Tsc1KO mice treated with placebo or Verteporfin. Bar, 1 mm. (c) Expression of indicated mRNAs was analyzed by qRT-PCR in kidney samples from Ctrl and mosaic-Tsc1KO mice treated with placebo or Verteporfin. n = 3 mice/group. Mean ± SEM; *, P < 0.05, **, P < 0.01. (d) Percentage of Ki67 and αSMA double-positive cells in α-SMA+ mesenchymal lesions in the indicated kidneys. Immunofluorescence staining and counting were performed on three sagittal sections from different kidney regions for each mouse. Representative images are shown. Mean ± SEM; n = 3 mice/group; **, P < 0.01; Bar, 100 µm. Insets show the lesions indicated with arrows. (e) In situ apoptotic cells were assessed by TUNEL assay on the kidney sections from Ctrl and mosaic-Tsc1KO mice treated with placebo or verteporfin. The number of TUNEL+ cells were counted in ten distinct fields of each section. Three sections were analyzed per each mouse. Representative images are shown. Arrows indicate TUNEL+ epithelial cells and arrowheads show TUNEL+ mesenchymal cells. Insets show the lesions indicated with arrows. Mean ± SEM; n = 3 mice/group; *, P < 0.05; Bar 100 µm.
Figure 6. Verteporfin treatment inhibits proliferation and induces apoptosis of Tsc1-null cells in vivo. Mice were administered i.p. with vehicle or verteporfin at a dose of 100 mg/kg every other day for 10 d before sacrifice. Mice were sacrificed at 6 wk of age. Three independent experiments were performed and mice in different treatments were pooled for analysis. (a) Kidney/body weight ratio of Ctrl and mosaic-Tsc1KO mice treated with placebo or Verteporfin. n = 3 mice/group. Mean ± SEM; *, P < 0.05, ***, P < 0.001. (b) Representative pictures of hematoxylin and eosin staining of kidney sections from Ctrl and mosaic-Tsc1KO mice treated with placebo or Verteporfin. Bar, 1 mm. (c) Expression of indicated mRNAs was analyzed by qRT-PCR in kidney samples from Ctrl and mosaic-Tsc1KO mice treated with placebo or Verteporfin. n = 3 mice/group. Mean ± SEM; *, P < 0.05, **, P < 0.01. (d) Percentage of Ki67 and αSMA double-positive cells in α-SMA+ mesenchymal lesions in the indicated kidneys. Immunofluorescence staining and counting were performed on three sagittal sections from different kidney regions for each mouse. Representative images are shown. Mean ± SEM; n = 3 mice/group; **, P < 0.01; Bar, 100 µm. Insets show the lesions indicated with arrows. (e) In situ apoptotic cells were assessed by TUNEL assay on the kidney sections from Ctrl and mosaic-Tsc1KO mice treated with placebo or verteporfin. The number of TUNEL+ cells were counted in ten distinct fields of each section. Three sections were analyzed per each mouse. Representative images are shown. Arrows indicate TUNEL+ epithelial cells and arrowheads show TUNEL+ mesenchymal cells. Insets show the lesions indicated with arrows. Mean ± SEM; n = 3 mice/group; *, P < 0.05; Bar 100 µm.CC BY-NC-SA · PubMed Central
Figure 7. Heterozygous deletion of Yap compromises the proliferation of renal mesenchymal lesions in mosaic-Tsc1KO mice. Three independent tamoxifen injection experiments were performed and female mice of indicated genotypes were pooled for analysis. (a) Kidney/body weight ratio of the indicated mice sacrificed at 6 wk of age (Ctrl, n = 4; mosaic-Tsc1KO, n = 5; mosaic-Tsc1KO;Yap+/−, n = 3). (b) Representative pictures of hematoxylin and eosin staining of kidney sections from the indicated mice. (c) Expression of indicated proteins was analyzed by immunoblot in mouse kidney samples from the indicated genotypes. (d) Percentage of Ki67 and α-SMA double-positive cells in α-SMA+ kidney lesions from mice of the indicated genotypes. Immunofluorescence staining and counting were performed on three sagittal sections from different kidney regions for each mouse (Ctrl, n = 4, mosaic-Tsc1KO, n = 5; mosaic-Tsc1KO;Yap+/−, n = 3). Insets show the lesions indicated with arrows. Bars, 100 µm. Mean ± SEM, **, P < 0.01. (e) Percentage of BrdU and Vimentin double-positive cells in Vimentin+ mesenchymal lesions in the indicated kidneys. BrdU (50 mg/kg) was injected i.p. 24 h before sacrifice. Immunofluorescence staining and counting were performed on three sagittal sections from different kidney regions for each mouse. Representative images are shown (Ctrl, n = 4; mosaic-Tsc1KO, n = 5; mosaic-Tsc1KO;Yap+/−, n = 3; mean ± SEM; **, P < 0.01; Bar, 100 µm). Insets show the lesions indicated with arrows. (f) Kidney/body weight ratio of Yap+/+ (n = 3) and Yap+/− (n = 3) mice. (g) Hematoxylin and eosin staining of kidney sections from Yap+/+ and Yap+/− mice. Bar, 1 mm. (h) Percentage of Ki67+ cells per mm2 in kidney sections from Yap+/+ and Yap+/− mice (n = 3). The number of Ki67+ cells were counted in 10 distinct fields per each section. Two sections were analyzed per each mouse.
Figure 7. Heterozygous deletion of Yap compromises the proliferation of renal mesenchymal lesions in mosaic-Tsc1KO mice. Three independent tamoxifen injection experiments were performed and female mice of indicated genotypes were pooled for analysis. (a) Kidney/body weight ratio of the indicated mice sacrificed at 6 wk of age (Ctrl, n = 4; mosaic-Tsc1KO, n = 5; mosaic-Tsc1KO;Yap+/−, n = 3). (b) Representative pictures of hematoxylin and eosin staining of kidney sections from the indicated mice. (c) Expression of indicated proteins was analyzed by immunoblot in mouse kidney samples from the indicated genotypes. (d) Percentage of Ki67 and α-SMA double-positive cells in α-SMA+ kidney lesions from mice of the indicated genotypes. Immunofluorescence staining and counting were performed on three sagittal sections from different kidney regions for each mouse (Ctrl, n = 4, mosaic-Tsc1KO, n = 5; mosaic-Tsc1KO;Yap+/−, n = 3). Insets show the lesions indicated with arrows. Bars, 100 µm. Mean ± SEM, **, P < 0.01. (e) Percentage of BrdU and Vimentin double-positive cells in Vimentin+ mesenchymal lesions in the indicated kidneys. BrdU (50 mg/kg) was injected i.p. 24 h before sacrifice. Immunofluorescence staining and counting were performed on three sagittal sections from different kidney regions for each mouse. Representative images are shown (Ctrl, n = 4; mosaic-Tsc1KO, n = 5; mosaic-Tsc1KO;Yap+/−, n = 3; mean ± SEM; **, P < 0.01; Bar, 100 µm). Insets show the lesions indicated with arrows. (f) Kidney/body weight ratio of Yap+/+ (n = 3) and Yap+/− (n = 3) mice. (g) Hematoxylin and eosin staining of kidney sections from Yap+/+ and Yap+/− mice. Bar, 1 mm. (h) Percentage of Ki67+ cells per mm2 in kidney sections from Yap+/+ and Yap+/− mice (n = 3). The number of Ki67+ cells were counted in 10 distinct fields per each section. Two sections were analyzed per each mouse.CC BY-NC-SA · PubMed Central
Figure 8. YAP is accumulated in TSC deficient cells due to blockage of autophagy. (a) Expression of indicated proteins was analyzed by immunoblot in Tsc2+/+ and Tsc2−/− MEFs treated with or without chloroquine (CQ) for 8 h. Similar results were observed in three independent experiments. (b, c) Localization of YAP and Lamp2 was analyzed by immunofluorescence in Tsc2+/+ and Tsc2−/− MEFs treated with or without CQ (20 µM) for 24 h. Insets show part of the cells indicated with squares. 50 cells were counted for yellow punctas in each group. Three independent experiments were performed and analyzed (mean ± SEM; *, P < 0.05, **, P < 0.01; Bar 10 µm). (d and e) Expression of indicated proteins was analyzed by immunoblot in Tsc2+/+, Tsc2−/− and Atg7+/+, Atg7−/− MEFs culturing with or without Torin1 for 24 h. Similar results were observed in three independent experiments. (f) Immunoblot analysis of YAP and LC3 in HeLa cells with indicated treatments. YAP levels were normalized with β-actin. Similar results were observed in three independent experiments. (g) Immunoprecipitation analysis of interacting proteins of flag-tagged YAP in the indicated culturing conditions for 0.5 h. Similar results were observed in three independent experiments. (h) Expression of indicated proteins was analyzed by immunoblot in ctrl (n = 3) and proximal tubule–specific Atg7 knockout mouse kidney samples (n = 3).
Figure 8. YAP is accumulated in TSC deficient cells due to blockage of autophagy. (a) Expression of indicated proteins was analyzed by immunoblot in Tsc2+/+ and Tsc2−/− MEFs treated with or without chloroquine (CQ) for 8 h. Similar results were observed in three independent experiments. (b, c) Localization of YAP and Lamp2 was analyzed by immunofluorescence in Tsc2+/+ and Tsc2−/− MEFs treated with or without CQ (20 µM) for 24 h. Insets show part of the cells indicated with squares. 50 cells were counted for yellow punctas in each group. Three independent experiments were performed and analyzed (mean ± SEM; *, P < 0.05, **, P < 0.01; Bar 10 µm). (d and e) Expression of indicated proteins was analyzed by immunoblot in Tsc2+/+, Tsc2−/− and Atg7+/+, Atg7−/− MEFs culturing with or without Torin1 for 24 h. Similar results were observed in three independent experiments. (f) Immunoblot analysis of YAP and LC3 in HeLa cells with indicated treatments. YAP levels were normalized with β-actin. Similar results were observed in three independent experiments. (g) Immunoprecipitation analysis of interacting proteins of flag-tagged YAP in the indicated culturing conditions for 0.5 h. Similar results were observed in three independent experiments. (h) Expression of indicated proteins was analyzed by immunoblot in ctrl (n = 3) and proximal tubule–specific Atg7 knockout mouse kidney samples (n = 3).CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 123 references

Cited by

See all 219

Metadata

Authors
Liang, N., Zhang, C., Dill, P., Panasyuk, G., Pion, D., Koka, V., Gallazzini, M., Olson, E. N., Lam, H., Henske, E. P., Dong, Z., Apte, U., Pallet, N., Johnson, R. L., Terzi, F., Kwiatkowski, D. J., Scoazec, J.-Y., Martignoni, G., & Pende, M.
Affiliations
  • Inserm (FR)
  • The University of Texas Southwestern Medical Center (US)
  • Brigham and Women's Hospital (US)
  • Charlie Norwood VA Medical Center (US)
  • University of Kansas Medical Center (US)
  • The University of Texas MD Anderson Cancer Center (US)
  • Hospices Civils de Lyon (FR)
  • University of Verona (IT)
Corresponding author
Pende, Mario
Venue
Journal of Experimental Medicine
Published
2014-10-06
Volume
211
Issue
11
Pages
2249-2263
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W2111900780
Cited by
205
References
122
Citations by year
2026: 10 · 2025: 8 · 2024: 13 · 2023: 14 · 2022: 23 · 2021: 24 · 2020: 23 · 2019: 24 · 2018: 19 · 2017: 17 · 2016: 13 · 2015: 15 · 2014: 1
FWCI
7.64
Type
journal article
Language
en
Open access
Locations
  • The Journal of Experimental Medicine (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, other-oa)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
Funders
  • Association pour la Recherche sur le Cancer
  • Institut National de la Santé et de la Recherche Médicale
  • China Scholarship Council
  • Institut National Du Cancer
  • National Cancer Institute (P01CA120964)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK096556)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Hippo pathway signaling and YAP/TAZ
  • Health Sciences › Medicine › Genetics (clinical) › Tuberous Sclerosis Complex Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords
tuberous sclerosis complex, YAP, mTOR, autophagy, Hippo signaling pathway, PEComa, TSC1, TSC2, protein degradation, lysosomes, organ size control, therapeutic target, tumor growth control
MeSH terms
Tuberous Sclerosis Complex 1 Protein, Verteporfin, YAP-Signaling Proteins, Animals, Autophagy, Cell Survival, Disease Models, Animal, Gene Expression Regulation, Humans, Immunohistochemistry, Kidney, Phosphoproteins, Porphyrins, Tuberous Sclerosis, Signal Transduction, Up-Regulation, Apoptosis, Angiomyolipoma, Mice, Knockout, Cell Cycle Proteins, Tumor Suppressor Proteins, Adaptor Proteins, Signal Transducing, Cell Proliferation, Mice, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex. https://app.cochat.ai/papers/10.1084/jem.20140341
The paper
Liang, N., Zhang, C., Dill, P., Panasyuk, G., Pion, D., Koka, V., Gallazzini, M., Olson, E. N., Lam, H., Henske, E. P., Dong, Z., Apte, U., Pallet, N., Johnson, R. L., Terzi, F., Kwiatkowski, D. J., Scoazec, J.-Y., Martignoni, G., & Pende, M. (2014). Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20140341

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.